All In Biotech

Drug Trial Radar · NCT01779206

ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer

Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer

Last checked: Nov 19, 2026Latest source record: Apr 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 4,936 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,936

Planned (sponsor's estimate)

Start

May 2012

Primary completion

Sep 2019

Study completion Jan 15, 2025

Sponsor

Lead sponsor
Women's Cancer Study Group GmbHAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 30, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Trial for the optimization of risk assessment and therapy success prediction in patients with early breast cancer by the use of biomarkers in advance to therapy decision-making to personalize therapies.

Conditions

  • Breast Cancer

Interventions

  • EpirubicinDrug

  • CyclophosphamideDrug

  • DocetaxelDrug

  • PaclitaxelDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Identification of a responder sub-population with intermediate and high risk, which due to therapy has outcome comparable to HR+/RS≤11Time frame: 3 Years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Breast Center of the University of Munich (LMU) Universitätsfrauenklinik Großhadern

    Munich, Bavaria, Germany

  • Ev. Krankenhaus Bethesda Brustzentrum Niederrhein

    Mönchengladbach, North Rhine-Westphalia, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.